Small gains in pancreatic and gastric cancers add up
Read More
One year of Herceptin optimal for HER2-positive breast cancer
How do we treat local recurrence of breast cancer?
Study confirms higher dose of Faslodex needed
Should women take 10 years of tamoxifen to prevent breast cancer recurrence?
Do you understand the goal of your cancer treatment?
Personalized medicine in the genomic age of breast cancer
Are new therapies in ER-positive breast cancer just the tip of the iceberg?
Embarking on a program for young adult cancer patients
Affordable Cancer Act upheld by Supreme Court
Super Herceptin?
New findings on chemotherapy for breast cancer
Another breakthrough in immunotherapy
Choosing wisely
Combination therapy – Can we hit the jackpot?
An update on the Cancer Genome Atlas for breast cancer
Video blog: Test could spare some DCIS patients from radiation
Video blog: HER2-targeted agents
Video blog: Complications with brachytherapy in breast cancer
Video blog: CLEOPATRA and pertuzumab in breast cancer
Video blog: BOLERO-2 and Afinitor in breast cancer
Preventing late recurrences – New insights from San Antonio
What to look for at this year's SABCS breast cancer meeting
Is pink demystifying and destigmatizing breast cancer?
Drug approvals: Are we in a new age yet?
Do the FDA Avastin hearings mark the end of an era?
The evolving PARP inhibitor story
A preview of ASCO – The new way of doing clinical trials
Navigating through the complex web of clinical trials
A few more answers (and questions) about the PARP inhibitor trials